An interview with Patrick Serruys, M.D., Ph.D., Imperial College London, principal investigator of the SYNTAX III Trial presented earlier this year as a late-breaker at EuroPCR. He presented the trial again at the Society of Cardiovascular Computed Tomography (SCCT) 2018 meeting.Â
He explains how noninvasive fractional flow reserve computed tomography (FFR-CT) was used in the study and compared to invasive angiography and pressure wire based FFR. Serruys, a well-known pioneer in interventional cardiology, had high praise for FFR-CT after seeing it in real-world cases. He said the technology can be used to better select patients who undergo cardiac CT scans to determine who needs to be revascularized in the cath lab. This can reduce the current issue where a lot of patients who have antomical diease on CT imaging turn out to not have a severe enough lesion to require stenting.